• About Us
  • Contact Us
  • Photo Gallery
  • Privacy Policy
  • Terms of Use
  • Citi TV
Sunday, June 4, 2023
Citinewsroom - Comprehensive News in Ghana
  • Home
  • News
  • Business
  • Sports
  • Showbiz
  • Coronavirus
  • Infographics
  • Livestream
  • Videos
No Result
View All Result
Citinewsroom - Comprehensive News in Ghana
  • Home
  • News
  • Business
  • Sports
  • Showbiz
  • Coronavirus
  • Infographics
  • Livestream
  • Videos
No Result
View All Result
Citinewsroom - Comprehensive News in Ghana
No Result
View All Result

FDA approves first herbal medicine for clinical trial on COVID-19 treatment

Ernest ArhinfulbyErnest Arhinful
February 1, 2021
Reading Time: 2 mins read
ShareShareShareShare

The Food and Drugs Authority (FDA) has approved a herbal medicine known as Cryptolepis sanguinolenta locally known as Nibima for clinical trials for the treatment of COVID-19.

It added that the trials will be conducted at two sites.

This was made known in a communiqué issued on Monday, February 1, 2021, and signed by Chief Executive Officer of FDA, Mrs. Delese A.A. Darko.

According to the Authority, the approval was granted in January 2021.

The statement disclosed that the herbal medicine was submitted by the “School of Public Health at the Kwame Nkrumah University of Science and Technology, (KNUST), submitted a clinical trial application in September 2020.”

“The Food and Drugs Authority (FDA), The National Medicine Regulatory Agency (NMRA) in Ghana, has approved a herbal medicine, Cryptolepis sanguinolenta, locally known as Nibima for clinical trials in January 2021.”

“In the search for a treatment for the ongoing COVID-19 pandemic, researchers from the School of Public Health at the Kwame Nkrumah University of Science and Technology, (KNUST), submitted a clinical trial application in September 2020 to assess the safety and efficacy of Cryptolepis sanguinolenta as a potential treatment for COVID-19. This follows results from laboratory studies conducted by the KNUST research team which points in the direction of possible clinical benefits.”

The Authority added that it gave the authorization after “detailed assessment.”

It insisted that it did so under (Section 150-166) of the Public Health Act 2012 (Act 851).

“The FDA after a detailed assessment of the application gave the requisite regulatory authority for the conduct of the trial as per the mandate outlined under Part 8 (Section 150-166) of the Public Health Act 2012 (Act 851), which gives the Authority the legal mandate to regulate clinical trials of drugs, herbal medicinal products, cosmetics or medical devices. The trial will be at two sites.”

Below is the full press statement from FDA

ShareTweetSendSend
Previous Post

Frances Adu-Mante appointed Board Chair of Absa Bank Ghana Limited

Next Post

Reintroducing social distancing in commercial vehicles will affect our revenue – GPRTU

Related Posts

Top Stories

Ghana’s unsustainable debt largely attributed to Energy Sector – World Bank Rep

June 4, 2023
Top Stories

We were actively developing Assin North before by-election – Gary Nimako

June 3, 2023

We’ll be swift with Ghana’s economic recovery – Ofori-Atta

June 3, 2023
Top Stories

Prioritise cases with Constitutional implications – CDD to Supreme Court

June 3, 2023
Top Stories

Endorsing Gyakye-Quayson for Assin North risky but justified – Amaliba

June 3, 2023
Top Stories

Two students of Osino Presbyterian SHS die in accident on Accra-Kumasi highway

June 3, 2023
Next Post

Reintroducing social distancing in commercial vehicles will affect our revenue - GPRTU

TOP STORIES

Ghana’s unsustainable debt largely attributed to Energy Sector – World Bank Rep

June 4, 2023

‘Ghanaians’ among dozens sentenced for roles in fraud, money laundering that stole over $30m in US

June 4, 2023

We were actively developing Assin North before by-election – Gary Nimako

June 3, 2023
Load More
ADVERTISEMENT
Citinewsroom – Comprehensive News in Ghana

CitiNewsroom.com is Ghana's leading news website that delivers high quality innovative, alternative news that challenges the status quo.

Archives

Download App

Download

Download

  • About Us
  • Contact Us
  • Photo Gallery
  • Privacy Policy
  • Terms of Use
  • Citi TV

© 2023 All Rights Reserved Citi Newsroom.

No Result
View All Result
  • Home
  • News
  • Business
  • Sports
  • Showbiz
  • Coronavirus
  • Infographics
  • Livestream
  • Videos

© 2023 All Rights Reserved Citi Newsroom.

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept All”, you consent to the use of ALL the cookies. However, you may visit "Cookie Settings" to provide a controlled consent.
Cookie SettingsAccept All
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
Performance
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Advertisement
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
Others
Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.
SAVE & ACCEPT